Therapeutic compounds

Patent metadata

Field	Value
Publication number	US-12441709-B2
Application number	US-202318225966-A
Country	US
Kind code	B2
Filing date	Jul 25, 2023
Priority date	Jan 29, 2016
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

The present invention relates to compounds that are antagonists of the orexin-1 receptor. The compounds have the structural formula (I) defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

First claim

The invention claimed is:

1. A method of treating a disease or condition selected from substance dependence, alcohol dependence, and nicotine dependence;
said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound which is selected from:
N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl)pyrazin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide; and
N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl)pyrimidin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide;
or a pharmaceutically acceptable salt or solvate thereof.

2. The method of claim 1 , wherein the compound is:
N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl) pyrazin-2-yl] amino} propan-2-yl] pyridine-2-carboxamide;
or a pharmaceutically acceptable salt or solvate thereof.

3. The method of claim 1 , wherein the compound is:
N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoro methyl) pyrimidin-2-yl]amino} propan-2-yl]pyridine-2-carboxamide;
or a pharmaceutically acceptable salt or solvate thereof.

4. The method of claim 1 , wherein the disease or condition is a substance dependence selected from cocaine, opiate, cannabis, alcohol, and prescription drug dependence.

5. The method of claim 4 , wherein the disease or condition is opiate dependence.

6. The method of claim 1 , wherein the compound is administered in combination with one or more other agents useful in the treatment of addictive disorders.

7. The method of claim 6 , wherein the one or more other agents useful in the treatment of addictive disorders are selected from buprenorphine, naloxone, naltrexone, and nalmefene.

8. The method of claim 7 , wherein the one or more other agents useful in the treatment of addictive disorders is buprenorphine.

9. The method of claim 1 , wherein the compound is administered orally.

10. The method of claim 1 , wherein the compound is administered in a solid oral dosage form.

11. The method of claim 1 , wherein the compound is administered in a dosage of between about 0.5 mg to about 500 mg of said compound.

12. The method of claim 11 , wherein the compound is administered in a dosage of between about 0.5 mg to about 100 mg of said compound.

13. The method of claim 11 , wherein the compound is administered in a dosage of 50, 100, 200 or 500 mg of said compound.

Assignees

• Indivior Uk Ltd

Inventors

• Martin Barrie Phillip

Classifications

• A61P19/10

  for osteoporosis · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/497 Primary

  containing further heterocyclic rings · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title